Loading
The first report of people in Brazil treated with a CAR-T cell therapy made entirely in a Brazilian public university, for leukaemia and lymphoma that had come back or stopped responding.
A two-centre retrospective report, published as a letter, from the Hospital das Clínicas de Ribeirão Preto and the Hospital das Clínicas de São Paulo (University of São Paulo). Twenty patients with relapsed or refractory B-cell non-Hodgkin lymphoma (7) or B-cell acute lymphoblastic leukaemia (13) were treated between 2019 and 2023 with an academic CD19-directed CAR-T product (HD37 clone, 4-1BB costimulatory domain). Lymphocytes were collected by apheresis, selected, activated, transduced and expanded, cryopreserved, and infused after lymphodepletion. The authors evaluated cytokine release syndrome, neurotoxicity (ICANS), cytopenias and response.
It is the evidence base for CARTHEDRALL, the multicentre trial meant to bring a national CAR-T to Brazil's public health system at a fraction of the price of imported products.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
Shares CD19-directed CAR-T cell therapy for refractory or relapsed acute lymphoblastic leukaemia or non-Hodgkin lymphoma (CARTHEDRALL), Fundação Hemocentro de Ribeirão Preto.
Shares CD19-directed CAR-T cell therapy for refractory or relapsed acute lymphoblastic leukaemia or non-Hodgkin lymphoma (CARTHEDRALL), Fundação Hemocentro de Ribeirão Preto.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/